Related Experiment Video

Updated: Aug 29, 2026

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

p21Waf1/Cip1 as a therapeutic target in breast and other cancers

Robert H Weiss1

  • 1Division of Nephrology, Department of Internal Medicine and Cancer Center University of California, Davis, California 95616, USA. rhweiss@ucdavis.edu

Cancer Cell
|January 7, 2004
PubMed

Insights

The cyclin-dependent kinase inhibitor p21 (CDK inhibitor p21) helps cells survive DNA damage. Inhibiting p21 in cancer cells may enhance chemotherapy effectiveness by disrupting repair mechanisms.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • The cyclin-dependent kinase inhibitor p21 (CDK inhibitor p21) was initially identified as a universal inhibitor of cyclin-dependent kinases.
  • Emerging evidence indicates p21 possesses functions beyond CDK inhibition, notably in cellular survival pathways.
  • Elevated p21 levels in certain cancers may confer a survival advantage to malignant cells.

Purpose of the Study:

  • To explore the antiapoptotic role of p21 in cellular response to DNA damage.
  • To evaluate the therapeutic potential of targeting p21 in cancer treatment strategies.
  • To investigate how modulating p21 affects the efficacy of DNA-damaging chemotherapeutic agents.

Main Methods:

  • Literature review and synthesis of existing research on p21 function.
  • Analysis of p21's role in DNA damage response and apoptosis.
  • Discussion of therapeutic strategies targeting p21 in oncology.

Main Results:

  • p21 plays a critical role in promoting cell survival following DNA damage and p53 activation, facilitating cellular repair.
  • The antiapoptotic function of p21 contributes to the survival advantage observed in some cancer cells.
  • Attenuation of p21 in malignant cells has the potential to interfere with DNA repair processes.

Conclusions:

  • The antiapoptotic activity of p21 presents a promising therapeutic target for cancer treatment.
  • Reducing p21 levels in cancer cells could sensitize them to DNA-damaging chemotherapy.
  • Targeting p21 may enhance the effectiveness of chemotherapeutic agents by subverting cancer cell repair mechanisms.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...